Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease

Abstract

Cabergoline at doses sufficient to suppress hyperprolactinaemia for a period of 3-4 years is not associated with an increased risk of clinically significant valvular regurgitation.